Regulus Therapeutics Inc. (NASDAQ:RGLS) shares traded up 2% during trading on Monday . The stock traded as high as $3.54 and last traded at $3.50, with a volume of 410,348 shares traded. The stock had previously closed at $3.43.

Several analysts recently weighed in on RGLS shares. FBR & Co reissued a “buy” rating and issued a $30.00 price objective on shares of Regulus Therapeutics in a report on Sunday, April 17th. Needham & Company LLC reissued a “buy” rating on shares of Regulus Therapeutics in a report on Tuesday, May 3rd. Cowen and Company reissued a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. BMO Capital Markets reissued a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. Finally, Wells Fargo & Co. started coverage on Regulus Therapeutics in a report on Tuesday, May 3rd. They issued a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $10.17.

The company’s 50-day moving average is $4.30 and its 200-day moving average is $5.89. The company’s market capitalization is $182.62 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.07. On average, equities research analysts predict that Regulus Therapeutics Inc. will post ($1.54) EPS for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.